CEPEGINTERFERON ALFA-2B

Summary

Cepeginterferon Alfa-2B (CHEMBL2108064) is a phase-3 clinical-stage unknown (ATC L03AB14); indicated across 1 condition including neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: L03AB14
• Indications: 1 condition
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108064
Name	CEPEGINTERFERON ALFA-2B
Type	Unknown
Max phase	3
ATC	L03AB14

Also known as: Algeron, Cepeginterferon alfa-2b, Pegylated human interferon a-2b, CEPEGINTERFERON ALFA-2B

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01740089	PHASE2/PHASE3	COMPLETED	Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C
NCT01889433	PHASE3	COMPLETED	An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C
NCT02103439	PHASE3	COMPLETED	An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).